tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kura Oncology initiated with a Neutral at Guggenheim

Guggenheim initiated coverage of Kura Oncology (KURA) with a Neutral rating and no price target The firm expects a near-term relapsed/refractory nucleophosmin 1-mutated acute myeloid leukemia launch for the company buy says it will be difficult to drive value with Syndax (SNDX_ already on market for this smaller patient population.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1